Transcription Factor Program 1

Transcription Factor Program 1 is an early-stage small-molecule drug candidate being developed by Talus Bio for the treatment of solid tumors. The program focuses on the modulation of an undisclosed transcription factor, a class of proteins traditionally considered difficult to target with conventional small molecules due to their lack of defined binding pockets. Talus Bio utilizes its proprietary platform to identify compounds that can disrupt or enhance the activity of these regulatory proteins within their native genomic environment. As of early 2024, the program is in the hit-to-lead phase of discovery, aiming to identify potent and selective molecules that can alter gene expression patterns associated with oncogenesis.